Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 2019

ABSTRACT: Background: Asthma and atopic dermatitis (AD) are chronic allergic conditions, along with allergic rhinitis and food allergy and cause high morbidity and mortality both in children and adults. This study aims to evaluate the global, regional, national and temporal trends of the burden of a...

Full description

Autores:
Buendía Rodríguez, Jefferson Antonio
Tipo de recurso:
Article of investigation
Fecha de publicación:
2023
Institución:
Universidad de Antioquia
Repositorio:
Repositorio UdeA
Idioma:
eng
OAI Identifier:
oai:bibliotecadigital.udea.edu.co:10495/45557
Acceso en línea:
https://hdl.handle.net/10495/45557
Palabra clave:
Asma
Asthma
Dermatitis Atópica
Dermatitis, Atopic
Eccema
Eczema
Carga Global de Enfermedades
Global Burden of Disease
Mortalidad
Mortality
Años de Vida Ajustados por Calidad de Vida
Quality-Adjusted Life Years
https://id.nlm.nih.gov/mesh/D001249
https://id.nlm.nih.gov/mesh/D003876
https://id.nlm.nih.gov/mesh/D004485
https://id.nlm.nih.gov/mesh/D000071219
https://id.nlm.nih.gov/mesh/D009026
https://id.nlm.nih.gov/mesh/D019057
Rights
openAccess
License
http://creativecommons.org/licenses/by-nc/2.5/co/
id UDEA2_9175b158075ffe693131fc198ba62a4e
oai_identifier_str oai:bibliotecadigital.udea.edu.co:10495/45557
network_acronym_str UDEA2
network_name_str Repositorio UdeA
repository_id_str
dc.title.spa.fl_str_mv Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 2019
title Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 2019
spellingShingle Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 2019
Asma
Asthma
Dermatitis Atópica
Dermatitis, Atopic
Eccema
Eczema
Carga Global de Enfermedades
Global Burden of Disease
Mortalidad
Mortality
Años de Vida Ajustados por Calidad de Vida
Quality-Adjusted Life Years
https://id.nlm.nih.gov/mesh/D001249
https://id.nlm.nih.gov/mesh/D003876
https://id.nlm.nih.gov/mesh/D004485
https://id.nlm.nih.gov/mesh/D000071219
https://id.nlm.nih.gov/mesh/D009026
https://id.nlm.nih.gov/mesh/D019057
title_short Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 2019
title_full Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 2019
title_fullStr Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 2019
title_full_unstemmed Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 2019
title_sort Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 2019
dc.creator.fl_str_mv Buendía Rodríguez, Jefferson Antonio
dc.contributor.author.none.fl_str_mv Buendía Rodríguez, Jefferson Antonio
dc.contributor.researchgroup.spa.fl_str_mv Grupo de Investigación en Farmacología y Toxicología
dc.subject.decs.none.fl_str_mv Asma
Asthma
Dermatitis Atópica
Dermatitis, Atopic
Eccema
Eczema
Carga Global de Enfermedades
Global Burden of Disease
Mortalidad
Mortality
Años de Vida Ajustados por Calidad de Vida
Quality-Adjusted Life Years
topic Asma
Asthma
Dermatitis Atópica
Dermatitis, Atopic
Eccema
Eczema
Carga Global de Enfermedades
Global Burden of Disease
Mortalidad
Mortality
Años de Vida Ajustados por Calidad de Vida
Quality-Adjusted Life Years
https://id.nlm.nih.gov/mesh/D001249
https://id.nlm.nih.gov/mesh/D003876
https://id.nlm.nih.gov/mesh/D004485
https://id.nlm.nih.gov/mesh/D000071219
https://id.nlm.nih.gov/mesh/D009026
https://id.nlm.nih.gov/mesh/D019057
dc.subject.meshuri.none.fl_str_mv https://id.nlm.nih.gov/mesh/D001249
https://id.nlm.nih.gov/mesh/D003876
https://id.nlm.nih.gov/mesh/D004485
https://id.nlm.nih.gov/mesh/D000071219
https://id.nlm.nih.gov/mesh/D009026
https://id.nlm.nih.gov/mesh/D019057
description ABSTRACT: Background: Asthma and atopic dermatitis (AD) are chronic allergic conditions, along with allergic rhinitis and food allergy and cause high morbidity and mortality both in children and adults. This study aims to evaluate the global, regional, national and temporal trends of the burden of asthma and AD from 1990 to 2019 and analyze their associations with geographic, demographic, social, and clinical factors. Methods: Using data from the Global Burden of Diseases (GBD), Injuries, and Risk Factors Study 2019, we assessed the age-standardized prevalence, incidence, mortality, and disability adjusted life years (DALYs) of both asthma and AD from 1990 to 2019, stratified by geographic region, age, sex, and socio-demographic index (SDI). DALYs were calculated as the sum of years lived with disability and years of life lost to premature mortality. Additionally, the disease burden of asthma attributable to high body mass index, occupational asthmagens, and smoking was described. Results: In 2019, there were a total of 262 million [95% UI: 224–309 million] cases of asthma and 171 million [95% UI: 165–178 million] total cases of AD globally; age-standardized prevalence rates were 3,416 [95% UI: 2,899–4,066] and 2,277 [95% UI: 2,192–2,369] per 100,000 population for asthma and AD, respectively, a 24.1% [95% UI: −27.2 to −20.8] decrease for asthma and a 4.3% [95% UI: 3.8–4.8] decrease for AD compared to baseline in 1990. Both asthma and AD had similar trends according to age, with age-specific prevalence rates peaking at age 5–9 years and rising again in adulthood. The prevalence and incidence of asthma and AD were both higher for individuals with higher SDI; however, mortality and DALYs rates of individuals with asthma had a reverse trend, with higher mortality and DALYs rates in those in the lower SDI quintiles. Of the three risk factors, high body mass index contributed to the highest DALYs and deaths due to asthma, accounting for a total of 3.65 million [95% UI: 2.14–5.60 million] asthma DALYs and 75,377 [95% UI: 40,615–122,841] asthma deaths. Conclusions: Asthma and AD continue to cause significant morbidity worldwide, having increased in total prevalence and incidence cases worldwide, but having decreased in age standardized prevalence rates from 1990 to 2019. Although both are more frequent at younger ages and more prevalent in high-SDI countries, each condition has distinct temporal and regional characteristics. Understanding the temporospatial trends in the disease burden of asthma and AD could guide future policies and interventions to better manage these diseases worldwide and achieve equity in prevention, diagnosis and treatment.
publishDate 2023
dc.date.issued.none.fl_str_mv 2023
dc.date.accessioned.none.fl_str_mv 2025-03-14T21:57:42Z
dc.date.available.none.fl_str_mv 2025-03-14T21:57:42Z
dc.type.spa.fl_str_mv Artículo de investigación
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.redcol.spa.fl_str_mv https://purl.org/redcol/resource_type/ART
dc.type.coarversion.spa.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/article
dc.type.version.spa.fl_str_mv info:eu-repo/semantics/publishedVersion
format http://purl.org/coar/resource_type/c_2df8fbb1
status_str publishedVersion
dc.identifier.issn.none.fl_str_mv 0105-4538
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/10495/45557
dc.identifier.doi.none.fl_str_mv 10.1111/all.15807
dc.identifier.eissn.none.fl_str_mv 1398-9995
identifier_str_mv 0105-4538
10.1111/all.15807
1398-9995
url https://hdl.handle.net/10495/45557
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.ispartofjournalabbrev.spa.fl_str_mv Allergy.
dc.relation.citationendpage.spa.fl_str_mv 2254
dc.relation.citationissue.spa.fl_str_mv 8
dc.relation.citationstartpage.spa.fl_str_mv 2232
dc.relation.citationvolume.spa.fl_str_mv 78
dc.relation.ispartofjournal.spa.fl_str_mv Allergy : European Journal of Allergy and Clinical Immunology
dc.rights.uri.*.fl_str_mv http://creativecommons.org/licenses/by-nc/2.5/co/
dc.rights.uri.spa.fl_str_mv https://creativecommons.org/licenses/by-nc/4.0/
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.coar.spa.fl_str_mv http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc/2.5/co/
https://creativecommons.org/licenses/by-nc/4.0/
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.extent.spa.fl_str_mv 22 páginas
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Wiley
dc.publisher.place.spa.fl_str_mv Copenhague, Dinamarca
institution Universidad de Antioquia
bitstream.url.fl_str_mv https://bibliotecadigital.udea.edu.co/bitstreams/77103cba-a9ec-42e4-9507-1e9b74ffcd8e/download
https://bibliotecadigital.udea.edu.co/bitstreams/66be202d-f4eb-4a12-9d99-6ddfba718c87/download
https://bibliotecadigital.udea.edu.co/bitstreams/cbe32748-5c1e-468a-8a41-a0e3b1bf704b/download
https://bibliotecadigital.udea.edu.co/bitstreams/a5cd6f6f-05d7-45b7-9bf6-73d9c922c233/download
https://bibliotecadigital.udea.edu.co/bitstreams/3b209222-4c8e-4bcf-88f1-7eb370889c06/download
bitstream.checksum.fl_str_mv b736cb49fd2e8a579bfac5d865a23b9e
8a4605be74aa9ea9d79846c1fba20a33
c0c92b0ffc8b7d22d9cf56754a416a76
60ff4ac6950fd3256b23207cb49dd3e3
5c79dd49ed4a44d6ce62e73855163afc
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional de la Universidad de Antioquia
repository.mail.fl_str_mv aplicacionbibliotecadigitalbiblioteca@udea.edu.co
_version_ 1851052617515401216
spelling Buendía Rodríguez, Jefferson AntonioGrupo de Investigación en Farmacología y Toxicología2025-03-14T21:57:42Z2025-03-14T21:57:42Z20230105-4538https://hdl.handle.net/10495/4555710.1111/all.158071398-9995ABSTRACT: Background: Asthma and atopic dermatitis (AD) are chronic allergic conditions, along with allergic rhinitis and food allergy and cause high morbidity and mortality both in children and adults. This study aims to evaluate the global, regional, national and temporal trends of the burden of asthma and AD from 1990 to 2019 and analyze their associations with geographic, demographic, social, and clinical factors. Methods: Using data from the Global Burden of Diseases (GBD), Injuries, and Risk Factors Study 2019, we assessed the age-standardized prevalence, incidence, mortality, and disability adjusted life years (DALYs) of both asthma and AD from 1990 to 2019, stratified by geographic region, age, sex, and socio-demographic index (SDI). DALYs were calculated as the sum of years lived with disability and years of life lost to premature mortality. Additionally, the disease burden of asthma attributable to high body mass index, occupational asthmagens, and smoking was described. Results: In 2019, there were a total of 262 million [95% UI: 224–309 million] cases of asthma and 171 million [95% UI: 165–178 million] total cases of AD globally; age-standardized prevalence rates were 3,416 [95% UI: 2,899–4,066] and 2,277 [95% UI: 2,192–2,369] per 100,000 population for asthma and AD, respectively, a 24.1% [95% UI: −27.2 to −20.8] decrease for asthma and a 4.3% [95% UI: 3.8–4.8] decrease for AD compared to baseline in 1990. Both asthma and AD had similar trends according to age, with age-specific prevalence rates peaking at age 5–9 years and rising again in adulthood. The prevalence and incidence of asthma and AD were both higher for individuals with higher SDI; however, mortality and DALYs rates of individuals with asthma had a reverse trend, with higher mortality and DALYs rates in those in the lower SDI quintiles. Of the three risk factors, high body mass index contributed to the highest DALYs and deaths due to asthma, accounting for a total of 3.65 million [95% UI: 2.14–5.60 million] asthma DALYs and 75,377 [95% UI: 40,615–122,841] asthma deaths. Conclusions: Asthma and AD continue to cause significant morbidity worldwide, having increased in total prevalence and incidence cases worldwide, but having decreased in age standardized prevalence rates from 1990 to 2019. Although both are more frequent at younger ages and more prevalent in high-SDI countries, each condition has distinct temporal and regional characteristics. Understanding the temporospatial trends in the disease burden of asthma and AD could guide future policies and interventions to better manage these diseases worldwide and achieve equity in prevention, diagnosis and treatment.COL003990222 páginasapplication/pdfengWileyCopenhague, Dinamarcahttp://creativecommons.org/licenses/by-nc/2.5/co/https://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 2019Artículo de investigaciónhttp://purl.org/coar/resource_type/c_2df8fbb1https://purl.org/redcol/resource_type/ARThttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionAsmaAsthmaDermatitis AtópicaDermatitis, AtopicEccemaEczemaCarga Global de EnfermedadesGlobal Burden of DiseaseMortalidadMortalityAños de Vida Ajustados por Calidad de VidaQuality-Adjusted Life Yearshttps://id.nlm.nih.gov/mesh/D001249https://id.nlm.nih.gov/mesh/D003876https://id.nlm.nih.gov/mesh/D004485https://id.nlm.nih.gov/mesh/D000071219https://id.nlm.nih.gov/mesh/D009026https://id.nlm.nih.gov/mesh/D019057Allergy.22548223278Allergy : European Journal of Allergy and Clinical ImmunologyPublicationORIGINALBuendiaJefferson_2023_Global_Regional_National_Burden_Allergic.pdfBuendiaJefferson_2023_Global_Regional_National_Burden_Allergic.pdfArtículo de investigaciónapplication/pdf1982415https://bibliotecadigital.udea.edu.co/bitstreams/77103cba-a9ec-42e4-9507-1e9b74ffcd8e/downloadb736cb49fd2e8a579bfac5d865a23b9eMD51trueAnonymousREADLICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://bibliotecadigital.udea.edu.co/bitstreams/66be202d-f4eb-4a12-9d99-6ddfba718c87/download8a4605be74aa9ea9d79846c1fba20a33MD53falseAnonymousREADCC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8933https://bibliotecadigital.udea.edu.co/bitstreams/cbe32748-5c1e-468a-8a41-a0e3b1bf704b/downloadc0c92b0ffc8b7d22d9cf56754a416a76MD52falseAnonymousREADTEXTBuendiaJefferson_2023_Global_Regional_National_Burden_Allergic.pdf.txtBuendiaJefferson_2023_Global_Regional_National_Burden_Allergic.pdf.txtExtracted texttext/plain100352https://bibliotecadigital.udea.edu.co/bitstreams/a5cd6f6f-05d7-45b7-9bf6-73d9c922c233/download60ff4ac6950fd3256b23207cb49dd3e3MD54falseAnonymousREADTHUMBNAILBuendiaJefferson_2023_Global_Regional_National_Burden_Allergic.pdf.jpgBuendiaJefferson_2023_Global_Regional_National_Burden_Allergic.pdf.jpgGenerated Thumbnailimage/jpeg16580https://bibliotecadigital.udea.edu.co/bitstreams/3b209222-4c8e-4bcf-88f1-7eb370889c06/download5c79dd49ed4a44d6ce62e73855163afcMD55falseAnonymousREAD10495/45557oai:bibliotecadigital.udea.edu.co:10495/455572025-03-27 01:08:57.235http://creativecommons.org/licenses/by-nc/2.5/co/open.accesshttps://bibliotecadigital.udea.edu.coRepositorio Institucional de la Universidad de Antioquiaaplicacionbibliotecadigitalbiblioteca@udea.edu.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